[Skip to Content]
[Skip to Content Landing]
Viewpoint
February 2015

Dermatologists, Imiquimod, and Treatment of Molluscum Contagiosum in ChildrenRighting Wrongs

Author Affiliations
  • 1Department of Dermatology, Kaiser Permanente, Pleasanton, California
JAMA Dermatol. 2015;151(2):125-126. doi:10.1001/jamadermatol.2014.3335

“Half of what we’re teaching you is wrong,” one of my medical school deans would often say. “The problem,” he would continue, “is that we don’t know which half.”

The dean was wise. Consider the case of imiquimod, long widely considered beneficial for treatment of molluscum contagiosum. It actually is not, as 2 large randomized clinical trials (RCTs) showed.1,2 The catch is that those 2 RCTs were never published. As a result, physicians—including, especially, dermatologists—continue to prescribe the drug for molluscum contagiosum in children. It’s time we stopped doing that.

First Page Preview View Large
First page PDF preview
First page PDF preview
×